Pharmaceuticals, Biotechnology and Life Sciences
UTRECHT, The Netherlands & PHILADELPHIA–(BUSINESS WIRE)–Lava Therapeutics B.V., today announced that it has entered into a research and license agreement…
Avacta said that Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge…
These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal.
Arctic Vision, a clinical stage biotechnology company focusing on the development and commercialization of innovative ophthalmology therapies in China and Asia, announced today the formation of its Scientific Advisory Board (SAB) comprised of three world-class ophthalmologists from China, the United States and the United Kingdom.
IRVINE, Calif.–(BUSINESS WIRE)–Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration…
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
PHILADELPHIA–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell…
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration,…